Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial.
Study Goal
The researchers aimed to determine the effects of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia.
Results Summary
Calcium-vitamin D supplementation significantly reduced fasting plasma glucose and serum triglycerides compared to placebo but had no effect on total, HDL, or LDL cholesterol levels.
Population
Iranian pregnant women at risk for pre-eclampsia, aged 18-35, in their third trimester with singleton pregnancies.
Effective Dosage
500 mg calcium carbonate plus 200 IU vitamin D3 daily.
Duration
9 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
calcium-vitamin D supplements | decrease | Fasting Plasma Glucose (FPG) | pregnant women at risk for pre-eclampsia | -9.1 mg dL(-1) | resulted in decreased | #1 |
calcium-vitamin D supplements | decrease | serum triglycerides levels | pregnant women at risk for pre-eclampsia | -11.7 mg dL(-1) | resulted in decreased | #2 |
calcium-vitamin D supplements | no change | serum total-cholesterol levels | pregnant women at risk for pre-eclampsia | no significant change | No significant differences were found | #3 |
calcium-vitamin D supplements | no change | HDL-cholesterol levels | pregnant women at risk for pre-eclampsia | no significant change | No significant differences were found | #4 |
calcium-vitamin D supplements | no change | LDL-cholesterol levels | pregnant women at risk for pre-eclampsia | no significant change | No significant differences were found | #5 |
placebo | increase | serum triglycerides levels | pregnant women at risk for pre-eclampsia | +49.9 mg dL(-1) | revealed a significant increase | #6 |
Increased metabolic profiles during pregnancy are associated with an increased risk of maternal and neonatal morbidity and remain a significant medical challenge. To our knowledge, no reports are available indicating the effects of calcium-vitamin D supplementation on metabolic profiles among pregnant women at risk for pre-eclampsia. This study was designed to determine the effects of consumption calcium-vitamin D supplements on metabolic profiles among Iranian pregnant women at risk for pre-eclampsia. This randomized single-blind controlled clinical trial was performed among 49 pregnant women at risk for pre-eclampsia, primigravida, aged 18-35 year old who were carrying singleton pregnancy at their third trimester. Subjects were randomly assigned to consume the placebo (n = 25) or calcium-vitamin D supplements (n = 24) for 9 weeks. Calcium-vitamin D supplements were containing 500 mg carbonate calcium plus 200 IU vitamin D3. Fasting blood samples were taken at baseline and after 9 week intervention to measures of Fasting Plasma Glucose (FPG) and serum lipid profiles. Consumption of calcium-vitamin D supplements resulted in decreased FPG and serum triglycerides levels as compared to the placebo (-9.1 vs. 0.5 mg dL(-1); p = 0.03, -11.7 vs. 49.9 mg dL(-1); p = 0.001, respectively). No significant differences were found comparing calcium-vitamin D supplements and the placebo in terms of their effect on serum total-, HDL-, LDL-cholesterol levels. Within-group differences in the placebo group revealed a significant increase in serum triglycerides levels (+49.9 mg dL(-1), p < 0.0001). In conclusion, consumption of calcium-vitamin D supplements for 9 weeks during pregnancy among pregnant women at risk for pre-eclampsia resulted in decreased FPG and serum triglycerides levels as compared to the placebo group, but could not affect serum total-, HDL-, LDL-cholesterol levels.